Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information
First Received Date ^†	May 30, 2006
Last Updated Date	May 30, 2006
Start Date ^†	May 2003
Current Primary Outcome Measures ^† (submitted: May 31, 2006)	IOP
Original Primary Outcome Measures ^†	Same as current
Change History	No Changes Posted
Current Secondary Outcome Measures ^†
Original Secondary Outcome Measures ^†

Descriptive Information
Brief Title ^†	Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Official Title ^†
Brief Summary	The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
Detailed Description
Study Phase	Phase III
Study Type ^†	Interventional
Study Design ^†	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Condition ^†	Ocular Hypertension
Intervention ^†	Drug: bimatoprost/timolol fixed combination
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^†	Completed
Enrollment ^†	440
Completion Date	September 2004
Primary Completion Date
Eligibility Criteria ^†	Inclusion Criteria: Clinical diagnosis of glaucoma or ocular hypertension in both eyes Patient requires IOP-lowering drug in both eyes Exclusion Criteria: Uncontrolled medical conditions Contraindication to beta-adrenoceptor antagonist therapy
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States, Austria, Canada, Germany
Expanded Access Status

Administrative Information
NCT ID ^†	NCT00332059
Responsible Party
Secondary IDs ^††
Study Sponsor ^†	Allergan
Collaborators ^††
Investigators ^†
Information Provided By	Allergan
Verification Date	May 2006
^† Required WHO trial registration data element. ^†† WHO trial registration data element that is required only if it exists.